

SWIXX SIGNS DEAL TO REPRESENT ALEXION IN RUSSIA & ANNOUNCES OPENING OF RUSSIA OPERATIONS

SWIXX ANNOUNCEMENT NO. 26

October 1st, 2019

Baar, Switzerland – Swixx BioPharma AG announces the extension of its existing Distribution Agreement with Alexion, a global biopharmaceutical company focused on serving patients and families affected by rare diseases, to now include Russia and Kazakhstan. With this extension, Swixx will be responsible for the commercial operations and delivery of Alexion’s medicines in Central & Eastern Europe and Russia. With the expansion into Russia, today Swixx also announces the opening of its first wholly-owned subsidiary in Russia (OOO Swixx Russia).

“It’s a great pleasure to not only announce another deal with Alexion, but also our own expansion into Russia,” commented Swixx CEO Jean-Michel Lespinasse. “We are delighted to welcome more than 30 pharmaceutical professionals who begin with Swixx Russia today. We are committed to building a strong Russian operation and are already laying plans to expand our Russian presence in the coming months beyond our partnership with Alexion.”

Under the terms of the extended agreement, Swixx will be responsible for the import, distribution and management of the in-market regulatory and pharmacovigilance requirements of Alexion’s currently-registered medicines in Russia as well as in Central & Eastern Europe.

About Swixx BioPharma AG

Swixx now operates fully-owned subsidiaries across Central and Eastern Europe, offering coverage from Moscow to Prague and from Tallinn to Sofia. Sales in 2018 exceeded 71 million Euros and in 2019 should reach 140 million Euros. Established in 2014, Swixx has gathered outstanding pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. The company specializes in representing research-based pharmaceutical, biotech, orphan, medical equipment and self-care brands. For more info about Swixx, please visit: www.swixxbiopharma.com

Contact:

Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

Note on Unsubscribing from Swixx Announcement Mailing List

In accordance with GDPR (General Data Protection Regulation) provisos of the EU, should you wish to unsubscribe / opt out of our mailing list, please send to Maja.Boskovic@swixxbiopharma.com a one-line message „Please unsubscribe me“ and your email address will be promptly removed from our mailing list.